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ABSTRACT
Early detection of cancer is a key element in successful treatment of the disease. Understanding the particular 
type of cancer involved, its origins and probable course, is also important. PhIP (2-amino-1-methyl-6 phenylimidazo 
[4,5-b]pyridine), a heterocyclic amine produced during the cooking of meat at elevated temperatures, has been shown to 
induce mammary cancer in female, Sprague-Dawley rats. Tumors induced by PhIP have been shown to contain discreet 
cytogenetic signature patterns of gains and losses using comparative genomic hybridization (CGH). To determine if a 
protein signature exists for these tumors, we are analyzing expression levels of the protein products of the above-
mentioned tumors in combination with a new bulk protein subtractive assay. This assay produces a panel of antibodies 
against proteins that are either on or off in the tumor. Hybridization of the antibody panel onto a 2-D gel of tumor or 
control protein will allow for identification of a distinct protein signature in the tumor. Analysis of several gene 
databases has identified a number of rat homologs of human cancer genes located in these regions of gain and loss. 
These genes include the oncogenes c-MYK, ERBB2/NEU, THRA and tumor suppressor genes EGR1 and HDAC3. The 
listed genes have been shown to be estrogen-responsive, suggesting a possible link between delivery of bio-activated
PhIP to the cell nucleus via estrogen receptors and gene-specific PhIP-induced DNA damage, leading to cell 
transformation.  All three tumors showed similar silver staining patterns compared to each other, while they all were 
different than the control tissue. Subsequent screening of these genes against those from tumors know to be caused by 
other agents may produce a protein signature unique to PhIP, which can be used as a diagnostic to augment optical and 
radiation-based detection schemes.
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1. INTRODUCTION
Proteins are the functional result of genetic expression.  Therefore they can be used to study the condition and health 
of the body and it’s components.  This is the emerging field of proteomics, which studies the proteins within a 
biosystem, their interactions, and patterns of expression in health and disease [1].  Proteins can be sampled from many 
biological sources including saliva, urine, hair, and blood.  Serum (blood minus cells and clotting factors) is the most 
valuable source for protein studies.  Blood supplies all of the body with necessary nutrients and also is a dumping ground 
for cellular waste and secretions.  Therefore, it contains a diverse collection of proteins that are representative of the 
condition of the body at a given time.  Secretions resulting from cell death or damage, tissue leakage proteins and 
aberrant proteins released from tumor cells can act as biomarkers for the disease or problem present [2].  Identification 
and classification of specific biomarkers resulting from a disease such as cancer can improve the chances of early
diagnosis and therefore increase the survival rate.  Ordinarily, by the time symptoms arise or a malignant tumor is 
palpable, the cancer has already begun to metastasize.  As is the case with ovarian cancer 80% of affected individuals are 
not diagnosed until the later stages of the disease, at which time the mortality rate is 35% after five years.  However, if 
this cancer is detected early on in stage I, 90% of patients survive, requiring only surgery for treatment [3]. Finding 
cancer before it finds the blood stream is an emerging field that hasn’t been substantially validated and therefore cannot 
yet be beneficial in a clinical setting.  The promise of a faster, non-invasive technique that can be used to diagnose 
pathology and determine health is the future of proteomic studies.
Most biomarkers indicative of disease or tissue damage are smaller then the kidney cut-off point for filtration. 
These proteins are low in abundance compared to many common plasma proteins (i.e. albumin and immunoglobulins) 
[3, 4].  Therefore, the study of the plasma proteome usually will include an efficient method to remove high abundance 
proteins, resulting in an enrichment of the remaining compounds [4].  After the serum has been depleted the remaining 
contents can be studied with presently available technologies, most commonly mass spectrometry or microarray analysis.
2. BIOMARKER DETECTION AND CLASSISFICATION
2.1 Mass spectrometry
Classically proteins have been studied using electrophoresis techniques of which 2-dimensional electrophoresis 
(2-DE) has been the most common approach.  The first dimension separates proteins by charge, also known as isoelectric 
focusing (IEF).  Proteins migrate through an immobilized pH gradient (IPG) until they encounter their point of 
isoelectricity.  The second dimension then separates the proteins by their molecular weight, following denaturation, using 
SDS PAGE [5].  This technique has been highly successful in the identification of genetic variants among the high 
abundance proteins within serum [4].  However, the study of biomarkers resulting from pathogenesis such as cancer 
requires the analysis of the serum proteins that are in low abundance.  This therefore must be performed after the 
common serum proteins are removed by fractionation or chromatographic methods resulting in an enrichment of the 
remaining species [4].  2-DE, although useful in separation ability, is unable to identify proteins beyond their size and 
charge.  To further classify proteins already characterized by 2-DE, mass spectrometry (MS) has offered promising 
results.  
Proteins resolved by two-dimensional gel electrophoresis can be digested from the gel with a proteolyitc 
enzyme after which the sample can be analyzed by MS [6].  SELDI-TOF (surface-enhanced laser desorption and 
ionization with time-of-flight) and MALDI-TOF (matrix-assisted laser desorption and ionization with time-of-flight) 
have been used to study protein profiles from whole and fractionated protein samples, respectively [1].  Like 2-DE, 
MALDI and SELDI produce spectra dependent on the protein or fragment’s size and electrical charge [3].  However, the 
determination is made as a result of the individual protein or fragment’s time of flight, which results in the position held 
along the sample’s spectra [3].    
With MALDI-TOF MS the protein sample is immobilized on a matrix that all the proteins within a sample 
interact with, but only a select few are bound to as a result of the matrix’s composition.  SELDI-TOF MS utilizes 
surfaces that bind specific proteins based on their particular absorption, partition, and electrostatic properties.  In both 
MS technologies the surfaces with bound proteins are pulsed with a laser causing ionization of the peptides, which then 
induces flight.  The TOF measurement is dependent on the charge and mass of the species being studied [1].  In order to 
account for such variables as the number of different compounds to the number of mass peaks observed, institution of 
appropriate bioinformatic tools is necessary [7].  Available online, Mascot software (www.matrixscience.com) can be 
used along with relevant sequence information obtained from NCBI (www.ncbi.nlm.nih.gov) to identify proteins from 
MALDI MS experiments [6].  MALDI is ideally used for proteins of low molecular weight (<20 kD) [1].  SELDI protein 
samples are purified of contaminants by use of an affinity-based surface from which wash steps can be applied to further 
purify the sample.  To analyze data received from SELDI MS ProPeak (3Z Informatics) offers a tool that applies Unified 
Maximum Separability Analysis (UMSA) based modules to produce linear results [7].  This tool is useful for identifying 
possible biomarkers for disease by locating variations between protein samples from affected and unaffected individuals.   
MALDI suffers from higher background signals as a result of the non-specific binding of materials to the matrix [7].  
Both of these technologies lack the ability to provide direct sequence data from protein mixtures [2, 6].  MALDI and
SELDI can however identify proteins accurately when the sample is digested and not extremely complex [6].   
2.2 DNA microarrays
To facilitate the study of expression patterns within specific cells or tissues of interest microarray technology 
has offered a high-throughput method for delivering rapid results [8].  The success of microarray technologies can be 
attributed primarily to databases containing sequence information that can be used to develop targets for investigation [8, 
9].  Microarrays can be used to study the genes expressed within a single cell, a collection of cells from a certain tissue, 
or even areas within a single cell where expression varies by location.  Individual cells can be collected using laser 
capture microdissection (LCM).  LCM utilizes a pulsed infrared laser that causes a thermoplastic film to adhere to 
selected cells of interest contained within a tissue sample.  This technique is especially useful in the segregation and 
collection of malignant cells that are surrounded by normal cells and stroma.  LCM is ideally suited for subsequent 
microarray analyses as it preserves subcellular compartments and compositions, enabling direct studies of the 
transcriptional and translational properties within the selected cell(s) [1].    
Relying on Watson and Crick base pairing for hybridization of nucleic acids, DNA microarrays can be used for 
analyses of transcript expression levels within single cells or whole tissue samples.  Additionally, DNA microarrays can 
be used to determine if a gene of interest is being expressed at all in a sample.  The key to this technology is using 
available sequence information to fabricate the probes that representative sample transcripts can be hybridized to.  The 
sequence of a gene of interest is used as a template to derive probes approximately 0.1-2.5 kb in size.  These probes are 
then spotted in a set orientation along the matrix of the microarray platform.  The probes are usually amplified by PCR 
and contain only a fraction of the genetic sequence for a complete gene and are then arrayed in a progressive fashion.  In 
this method not only is the presence/absence of the gene of interest being studied, but also the concentration of 
transcripts that are homologous to particular regions within the gene can be observed [8, 10].  Two techniques for 
spotting the probe onto the matrix are currently employed; they are mechanical microspotting and ink jetting [8].  With 
mechanical microspotting a pin loaded with the probe DNA makes contact with the matrix upon dispensing while ink 
jetting utilizes a propulsion mechanism to release the probe without making contact [8, 11-13].  The matrix the probe 
adheres to is usually made of either glass or nylon, each of which has certain advantages [8].  After the matrix is 
prepared with probe DNA, the targets must be manufactured.  First, mRNA from the sample of interest is collected and 
then converted to cDNA by reverse transcriptase (RT).  RT is an enzyme used by viruses to convert mRNA into DNA, 
the opposite of what occurs in the cellular process of making protein  (DNA → mRNA → protein).  The target cDNA 
must be labeled to quantify the results after hybridization to the probe.  33P dCTP is a low emission radioactive label that 
can be incorporated into the target for data analysis.  The use of a low energy emitter is preferred so that signals of 
adjacent weak and strong hybridization patterns can be differentiated [8, 10].  Fluorescence can also be used to label the 
target and is preferential to radioactive labeling when studying competitive hybridization reactions.  Targets from two 
separate samples can be labeled with Cy3-dUTP and Cy5-dUTP respectively, from which the excitation wavelength for 
emission is widely separated, allowing optical filtration that is highly discriminatory [8, 10].  Although fluorescent 
labeling does have its advantages, it requires a large amount of target to be detectable (>10 μg), whereas radioactive 33P 
labeling only requires a minimal amount for detection (0.1 μg) [8].  
Extracting the data from a DNA microarray experiment for analysis has been approached with many different 
techniques and remains to be standardized.  The first level of analysis involves the removal of background, and 
normalization from which the data can be statistically interpreted.  Although the use of statistical methods is most 
common in microarray analysis there are many variants on this approach that are currently utilized.  Commercially 
available bioinformatic programs are presently available to sort through the results of a DNA microarray experiment, 
however they too rely on complicated statistical calculations.  A substantial amount of variables are included in a typical 
microarray experiment leading to the daunting task of locating and eliminating false positives and negatives with 
reference to transcript expression levels.  In order to increase the reliability and validity of these experiments, the 
incorporation of replicates within a single experiment has been shown to reduce the amount of misclassifications [14].  
2.3 Protein microarrays
DNA microarrays are only capable of revealing information about the mRNA content within a cell, which is a 
long step off from the functional side of protein expression.  As a result protein and antibody arrays have been useful in 
elucidating protein specific interactions that are a result of post-transcriptional modifications.  These alterations can’t be 
determined or predicted by the sequence information contained in the mRNA transcript [15].  Protein arrays can be used 
to study protein-DNA, protein-protein, and protein-small molecule interactions.  The protein of interest is immobilized 
on a matrix and then incubated with the labeled potential substrate to ascertain interactions.  Protein microarrays can also 
be used to study enzymatic activity with the enzyme, either functioning as the immobilized species or being added to 
immobilized substrate [16].  Although these applications have offered advanced methods for studying the behaviors and 
interactions of proteins, the potential for disease diagnostics and target identifications is where most of the research 
utilizing protein and antibody microarrays is currently focused.    
The key to a protein microarray is to maintain native structure while immobilizing the arrayed species on a 
particular surface.  These microarrays are specifically studying the proteins functions or characteristics, which can only 
be observed when the compounds withhold their natural characteristics.  Therefore, a significant amount of time and 
research efforts have been focused on finding the optimal surface for proteins and antibodies to adhere to without 
interfering with detection of the results.  Nitrocellulose offers a support that proteins can interact with in a non-covalent, 
and non-polar process, therefore not altering the structure of the immobilized species.  However, these surfaces allow for 
high background signals as a result of non-specific binding by the test sample.  This can be avoided with use of a 
blocking reagent such as BSA.  Glass surfaces that are specifically treated with immobilized nickel ions or agarose to 
increase the binding capabilities of the protein have been used [17, 18].  Treated glass surfaces form covalent bonds with 
the arrayed protein, which can alter the structure of the protein resulting in possible reduction in binding affinity to the 
target.  In order to prevent this, research has been performed on glass coated with polyacrylamide based hydrogels and 
poly-1-lysine treated glasses both of which have shown high binding efficiencies and can aid in the maintenance of 
native structure and reactivity [19].  PVDF, polystyrene and gold are other surfaces used in the binding of proteins in 
microarray research, however they are not easily attained or cost effective [15].    
Protein microarrays can be performed either with antibodies immobilized in an array that protein mixtures can 
then be incubated onto, or with a protein sample immobilized on the surface to which antibodies are then targeted to.  
Forward phase arrays are those with the antibodies immobilized on a surface to which only a specific substrate can bind.  
By choosing the antibodies for immobilization, the specific substrate that will bind is already understood and the 
experiment is performed with the purpose of observing whether or not the analyte is present in a sample [1].  The 
detection and interpretation of the results of a forward phase antibody array can be performed by two methods.  The 
sandwich method which requires a second antibody with a fluorescent label to be applied to the bound analyte, or by 
fluorescently labeling the analyte before incubation on the microarray [15].  Forward phase arrays have low sensitivity 
and suffer from the possibility of not containing a high enough concentration of antibodies for all the antigens in the test 
sample [1].  Reverse phase arrays have been more popular for studying a single biological component.  In this set-up a 
complete tissue lysate can be contained in a single spot within an array so that multiple samples can be probed for the 
same compound.  An optimized antibody with a fluorescent label is chosen to use as a probe for the arrayed tissue lysate. 
Therefore, only a single antigen is being targeted within a complete biological sample [20].  Protein microarrays are 
useful in identifying changes in protein expression and can even be used to classify new targets for disease diagnosis and 
treatment.  Handling and maintaining the delicate structure of proteins requires further research to be performed in the 
field of protein microarrays.  
3. FUTURE PROSPECTS
Many of the most common and deadliest diseases are known to be at some level under genetic control.  So it 
would only be obvious to look at the genetic content of affected individuals for a target to design treatments against.  
However, it is understood that gene content, expression and functionality all play an important and individual role in 
disease development and therefore must be studied with a variety of different techniques.  Before drugs can be 
manufactured, a target must be identified and thus far most changes related to disease are amongst compounds also 
present in the healthy state.  Setting a baseline that can be directly correlated to the healthy state is the most challenging 
and controversial aspect of proteomic research.   It has been shown that concentration variations have been observed 
within the plasma proteome based on the time of day, age, gender, season, diet, and sleep patterns of the individual being 
screened [21-25].  Even the posture of the subject under investigation can change the concentration of the protein within 
the blood by 10% due to arterial pressure increases when standing versus sitting [26].  Therefore measuring an increase 
or decrease in the concentration of a protein that is linked to disease is not enough to predict illness.  With current 
technologies such as mass spectrometry and microarrays, identification of biomarkers for disease is possible.  However, 
setting a baseline for healthy concentrations versus diseased levels will have to be based on the individual being tested.  
This still lacks 100% reliability, which begs the question of can we find biomarkers that are only expressed in the disease 
state?  This relies on finding genes and/or proteins that are only found in diseased tissue such as a cancer cell and then 
designing drugs against them.  Of the available technologies not one can do the job by itself, they all must be combined 
in a time and economically efficient way to achieve any sort of progress in the discovery of potential biomarkers for 
disease diagnosis [27].       
This work was performed under the auspices of the U. S. Department of Energy by the University of California, 
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